GLP-1 medications and the gut microbiome: what a 2026 review found

The emerging field of pharmacomicrobiomics studies how gut bacteria influence drug action. The premise is that trillions of microorganisms in the gastrointestinal tract don't just sit there — they produce metabolites, influence hormone signaling, and interact with the immune system in ways that may alter how medications work.

For GLP-1 drugs, this raises a specific question: if your gut bacteria partially regulate how much GLP-1 your body naturally produces, and if GLP-1 drugs work partly by amplifying that system, then could the state of your microbiome affect how well the drug performs? That's exactly what the Kamath review examines.

The gut microbiome helps regulate the body's natural production of GLP-1, a hormone secreted by cells in the intestinal lining. Two primary mechanisms are described in the review.

Short-chain fatty acids. When gut bacteria break down dietary fiber, they produce short-chain fatty acids (SCFAs) — including acetate, propionate, and butyrate. These activate receptor proteins (GPR41 and GPR43) on intestinal cells, which can stimulate GLP-1 release. Butyrate also influences gene expression in a way that supports ongoing hormone production.

Bile acids. Gut bacteria convert primary bile acids (produced by the liver) into secondary bile acids. These activate a receptor called TGR5, which promotes GLP-1 secretion. A different receptor, FXR, suppresses GLP-1 when activated — creating a dynamic interplay mediated by microbial metabolism.

Inflammation and dysbiosis. In a disrupted microbiome (dysbiosis), higher levels of lipopolysaccharide from bacteria activate inflammatory pathways. This chronic inflammation may reduce the effectiveness of insulin signaling and impair how well GLP-1 receptor agonists work, the review suggests.

The implication: individuals with healthier gut microbiomes may produce more endogenous GLP-1 and respond better to GLP-1 medications — though this is a hypothesis, not a confirmed clinical fact.

GLP-1 medications change how much you eat, how quickly food moves through your gut, and how bile acids circulate. All of these factors can alter microbial composition over time.

The review reports that clinical and preclinical studies found GLP-1 receptor agonists — including liraglutide, semaglutide, and dulaglutide — may increase the abundance of Akkermansia muciniphila, a bacterial species associated with metabolic health, and in some studies shift the balance of Bacteroidetes and Firmicutes. Some trials showed increased microbial diversity; others found minimal changes. Results varied across studies.

Importantly, the review notes that these changes may not be caused directly by the drugs. Weight loss and reduced caloric intake can independently alter microbial communities. Metformin, often taken alongside GLP-1 drugs in T2D, also reshapes the microbiome. Separating drug effects from these confounders in human studies is genuinely difficult.

One of the more intriguing findings in the review involves a pilot study of 52 individuals with type 2 diabetes. Patients who responded well to GLP-1 treatment had distinct baseline microbial profiles compared to those who didn't respond as strongly. Certain species — Bacteroides dorei and Roseburia inulinivorans — were associated with greater reductions in blood glucose (HbA1c).

Machine learning models built from microbial data showed "promising, though preliminary, predictive accuracy" in small cohorts.

This is an early signal worth watching. It is not a basis for clinical action. A pilot study of 52 patients cannot establish causal relationships or generate clinical protocols. It generates hypotheses for larger, controlled studies to test.

You may be wondering whether you should change your diet, take a probiotic, or request microbiome testing before starting a GLP-1 medication. Here's what the current evidence supports:

• There is no established clinical protocol for optimizing the gut microbiome before or during GLP-1 therapy
• No probiotic supplement has been shown to enhance GLP-1 medication response in human clinical trials
• Dietary fiber supports SCFA production, which supports natural GLP-1 secretion — but this is a general health recommendation, not a GLP-1 optimization strategy with clinical evidence
• Microbiome testing services exist commercially, but there is no evidence base for using them to guide GLP-1 prescribing decisions

What you can reasonably take from this research: there may be biological reasons, beyond the well-known factors of dose and duration, that influence individual GLP-1 response. This is a legitimate area of scientific inquiry that may eventually inform more personalized therapy. It's not there yet.

The review's own conclusions are carefully hedged: "causal evidence in humans remains limited." This is honest and important. Most of the mechanistic evidence comes from animal models or in vitro studies. Human clinical trials that systematically manipulate the microbiome to test GLP-1 outcomes don't yet exist.

The authors call for "controlled dietary parameters, longitudinal follow-up, and microbiome-targeted interventions" in future research. That's a research agenda, not current clinical guidance.

• If I'm not responding to my GLP-1 medication as expected, what factors do you typically look at first?
• Do you know of any clinical trials exploring microbiome factors in GLP-1 response that I might qualify for?
• Is there anything about my diet, GI history, or prior antibiotic use that could be worth discussing in relation to how this medication works?
• Are there aspects of my metabolic health beyond weight and glucose that you're tracking on this medication?

• GI symptoms during GLP-1 treatment — nausea, bloating, and motility changes may reflect both drug effects and microbiome interactions
• Medication response over the first 12–24 weeks — if you're not seeing expected changes, raise that with your prescriber rather than attributing it to microbiome factors without clinical input
• Diet quality and fiber intake — not as a GLP-1 optimization strategy, but as a general factor in metabolic health

Your gut bacteria and your GLP-1 medication are probably having a conversation. The review by Kamath and colleagues (2026) provides a detailed map of how that conversation might work. What it doesn't provide is a protocol for changing the outcome of that conversation in a clinical setting.

If you have questions about how your gut health might affect your GLP-1 therapy, bring them to your prescriber — who can help you separate early-stage science from what's actionable in your care.

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• Kamath S, Chan NSL, Joyce P. (2026). GLP-1 agonists and the gut microbiome: A bidirectional relationship. British Journal of Clinical Pharmacology. DOI: 10.1002/bcp.70487. PubMed PMID 41703894. bpspubs.onlinelibrary.wiley.com
• News-Medical (Feb 19, 2026). Gut microbiome may shape response to GLP-1 drugs, new review suggests. news-medical.net